Wikisage, the free encyclopedia of the second generation, is digital heritage
Molnupiravir: Difference between revisions
No edit summary |
|||
| (3 intermediate revisions by the same user not shown) | |||
| Line 6: | Line 6: | ||
===EIDD 2801=== | ===EIDD 2801=== | ||
[https://www.nature.com/articles/s41564-020-00835-2 Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets] | [https://www.nature.com/articles/s41564-020-00835-2 Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets] | ||
==Source== | ==Source== | ||
[https://enwiki.miraheze.org/w/index.php?title=Molnupiravir&oldid=2390 enWiki(Miraheze)] | [https://enwiki.miraheze.org/w/index.php?title=Molnupiravir&oldid=2390 enWiki(Miraheze)] | ||
{{Wikidata|Q96376832}} | |||
{{refs}} | |||
Latest revision as of 14:20, 27 January 2021
Molnupiravir (development codes EIDD-2801 and MK-4482) is an investigational antiviral drug for oral administration for the treatment of influenza. It is an N4-hydroxycytidine-donating prodrug, a nucleoside derivative known to be mutagenic that acts against RNA viruses by introducing errors in RNA replication by the viral RNA-dependent RNA polymerase. It also has some activity against coronaviruses such as SARS-CoV, MERS-CoV and SARS-CoV-25, responsible for SARS, MERS and COVID-19 respectively. It was developed at Emory University in Atlanta, Georgia, before being acquired by Ridgeback Biotherapeutics in Miami, Florida, which has partnered with Merck & Co. for further development. [1]
External Links
Coronavirus RNA Proofreading Molecular basis and therapeutic target
EIDD 2801
Source
| References: |